An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Nesina

Chemical Namealogliptin
Dosage FormTablet (oral; 6.25mg, 12.5mg, 25mg)
Drug ClassInhibitors
SystemEndocrine
CompanyTakeda Pharmaceutical Company Limited
Approval Year2013

Indication

  • Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 4/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nesina (alogliptin) Prescribing Information2013Takeda Pharmaceuticals America, Inc. Deerfield, IL
Document TitleYearSource
Real‑world adherence, persistence, and in‑class switching during use of dipeptidyl peptidase‑4 inhibitors: a systematic review and meta‑analysis involving 594,138 patients with type 2 diabetes. 2020Acta Diabetologica
Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis.2018Diabetes Therapy
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. 2018Acta Diabetologica
Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 Diabetes: A systematic review and network meta-analysis. 2017Diabetes Therapy
Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: A systematic review and network meta-analysis. 2017Clinical Therapeutics
Cardiovascular safety of incretin-based therapies in type 2 diabetes: Systematic review of integrated analyses and randomized controlled trials.2017Advances in Therapy
Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a network meta-analysis.2017Value in Health
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.2017PLoS One
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.2017CMAJ Open
Document TitleYearSource
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2020European Heart Journal
Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update.2020Canadian Journal of Diabetes